Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.97 |
| ▸ | ABCG2 | Q9UNQ0 | 12/20 | 0.86 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.79 |
| ▸ | PDE5A | O76074 | 3/20 | 0.78 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | TP53 | P04637 | 2/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7280956 | 0.93 | ABCG2 (1.00) | MEN1KMT2AABCG2L3MBTL1PDE5A | |
| SCHEMBL13945465 | 0.92 | MEN1 (0.82) | MEN1KMT2AABCG2L3MBTL1PDE5A | |
| SCHEMBL5526966 | 0.92 | MEN1 (0.82) | MEN1KMT2AABCG2L3MBTL1PDE5A | |
| SCHEMBL1083771 | 0.90 | MEN1 (0.98) | MEN1KMT2AABCG2L3MBTL1PDE5A | |
| SCHEMBL13945468 | 0.85 | ABCG2 (1.00) | MEN1KMT2AABCG2PDE5AABCC1 | |
| SCHEMBL3890403 | 0.84 | MAPT (0.83) | MEN1KMT2AABCG2L3MBTL1PDE5A | |
| SCHEMBL1058652 | 0.84 | ABCG2 (1.00) | MEN1KMT2AABCG2PDE5AMAPT | |
| SCHEMBL22201624 | 0.83 | ABCG2 (0.83) | MEN1KMT2AABCG2L3MBTL1PDE5A | |
| SCHEMBL1063103 | 0.83 | ABCG2 (1.00) | MEN1KMT2AABCG2PDE5AABCC1 | |
| SCHEMBL5532972 | 0.81 | MAPT (0.69) | MEN1KMT2AABCG2L3MBTL1PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023773-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | TRPV1, TRPV2, TRPA1 | MEN1 4478/4885KMT2A 3931/4885ABCG2 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.